J Cañueto1,2, E Cardeñoso3, J L García2,4, Á Santos-Briz1,2, A Castellanos-Martín2,4, E Fernández-López1,2, A Blanco Gómez2,4, J Pérez-Losada2,4, C Román-Curto1,2. 1. Departamento de Dermatología, Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. 2. Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, 37007, Salamanca, Spain. 3. Departamento de Dermatología, Hospital Virgen de la Concha, Avenida de Requejo, Zamora, Spain. 4. Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Universidad de Salamanca/CSIC, Campus Miguel de Unamuno, s/n. 37007, Salamanca, Spain.
Abstract
BACKGROUND: Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans after basal cell carcinoma, and its incidence is dramatically rising. CSCC is rarely problematic, but given its high frequency, the absolute number of complicated cases is also high. It is necessary to identify molecular markers in order to recognize those CSCCs with poor prognosis. There is controversy concerning the role of epidermal growth factor receptor (EGFR) as a marker of prognosis in CSCC. In addition, EGFR-targeted therapies have emerged in recent years and a better understanding of the role of EGFR in CSCC may be of help for some patients in predicting prognosis and guiding curative management. OBJECTIVES: To evaluate the role of EGFR as a prognostic factor in CSCC. METHODS: We evaluated clinical and histopathological features, including events of poor clinical evolution, in a series of 94 cases of CSCC. We also analysed EGFR expression by immunohistochemistry, fluorescent in situ hybridization and quantitative polymerase chain reaction. RESULTS: We detected EGFR in 85 cases (90%), with overexpression in 33 cases (35%), and aberrant EGFR expression in the cytoplasm in 50 cases (53%). EGFR overexpression in the primary tumours was associated with lymph node progression, tumour-nodes-metastasis stage progression and proliferation (Ki-67 staining) in CSCC. EGFR overexpression and poor grade of differentiation were the strongest independent variables defining lymph node metastasis and progression in CSCC in a logistic regression model. CONCLUSIONS: We demonstrate that EGFR overexpression has prognostic implications associated with lymph node metastasis and progression in CSCC.
BACKGROUND:Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans after basal cell carcinoma, and its incidence is dramatically rising. CSCC is rarely problematic, but given its high frequency, the absolute number of complicated cases is also high. It is necessary to identify molecular markers in order to recognize those CSCCs with poor prognosis. There is controversy concerning the role of epidermal growth factor receptor (EGFR) as a marker of prognosis in CSCC. In addition, EGFR-targeted therapies have emerged in recent years and a better understanding of the role of EGFR in CSCC may be of help for some patients in predicting prognosis and guiding curative management. OBJECTIVES: To evaluate the role of EGFR as a prognostic factor in CSCC. METHODS: We evaluated clinical and histopathological features, including events of poor clinical evolution, in a series of 94 cases of CSCC. We also analysed EGFR expression by immunohistochemistry, fluorescent in situ hybridization and quantitative polymerase chain reaction. RESULTS: We detected EGFR in 85 cases (90%), with overexpression in 33 cases (35%), and aberrant EGFR expression in the cytoplasm in 50 cases (53%). EGFR overexpression in the primary tumours was associated with lymph node progression, tumour-nodes-metastasis stage progression and proliferation (Ki-67 staining) in CSCC. EGFR overexpression and poor grade of differentiation were the strongest independent variables defining lymph node metastasis and progression in CSCC in a logistic regression model. CONCLUSIONS: We demonstrate that EGFR overexpression has prognostic implications associated with lymph node metastasis and progression in CSCC.
Authors: Luke S McLean; Tessa A Morris; Ann Gramza; Stephen Liu; Saad A Khan; A Dimitrios Colevas; Tillman Pearce; Danny Rischin Journal: Invest New Drugs Date: 2022-04-18 Impact factor: 3.651
Authors: Benjamin Kansy; Christoph Aderhold; Lena Huber; Sonja Ludwig; Richard Birk; Anne Lammert; Stephan Lang; Nicole Rotter; Benedikt Kramer Journal: Cancer Genomics Proteomics Date: 2020 Sep-Oct Impact factor: 4.069
Authors: William N William; Lei Feng; Renata Ferrarotto; Lawrence Ginsberg; Merrill Kies; Scott Lippman; Bonnie Glisson; Edward S Kim Journal: J Am Acad Dermatol Date: 2017-09-28 Impact factor: 11.527
Authors: Mary B Kelley; Taylor J Geddes; Maria Ochiai; Noah M Lampl; W Wade Kothmann; Sara R Fierstein; Victoria Kent; Kathleen DeCicco-Skinner Journal: PLoS One Date: 2022-03-24 Impact factor: 3.240